X0306 4 2021-12-31 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400971 Campbell Bradley L C/O AMICUS THERAPEUTICS, INC. 3675 MARKET STREET PHILADELPHIA PA 19104 1 1 0 0 Chief Operating Officer Common Stock 2021-12-31 4 F 0 17597 11.55 D 439671 D Common Stock 2022-01-02 4 F 0 27946 11.55 D 411725 D Common Stock 2022-01-03 4 F 0 4984 12.11 D 406741 D Common Stock 2022-01-03 4 M 0 5470 3.53 A 412211 D Common Stock 2022-01-03 4 S 0 5470 11.8611 D 406741 D Common Stock 2022-01-03 4 A 0 154711 A 561452 D Common Stock 2022-01-04 4 F 0 7368 12.48 D 554084 D Stock Options (right to buy) 3.53 2022-01-03 4 M 0 5470 0.00 D 2023-01-28 Common Stock 5470 60185 D Stock Options (right to buy) 12.11 2022-01-03 4 A 0 283555 0.00 A 2032-01-03 Common Stock 283555 283555 D The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.36 to $12.11. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023. All of the options were fully vested and exercisable as of the transaction date. These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. /s/ Christian Formica, Attorney-in-Fact 2022-01-04